Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Annovis Bio in a research note issued on Monday, June 9th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.42) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Annovis Bio's current full-year earnings is ($2.19) per share. HC Wainwright also issued estimates for Annovis Bio's Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.66) EPS.

Annovis Bio (NYSE:ANVS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.15.

Separately, Canaccord Genuity Group decreased their price target on shares of Annovis Bio from $26.00 to $17.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Annovis Bio presently has a consensus rating of "Buy" and an average target price of $30.25.

Annovis Bio Stock Performance

Shares of ANVS stock traded down $0.13 on Tuesday, hitting $2.82. The company's stock had a trading volume of 371,950 shares, compared to its average volume of 740,647. The stock's 50 day moving average is $1.89 and its 200-day moving average is $3.05. Annovis Bio has a fifty-two week low of $1.11 and a fifty-two week high of $17.88. The company has a market capitalization of $54.85 million, a PE ratio of -0.63 and a beta of 1.62.

Institutional Investors Weigh In On Annovis Bio

A number of large investors have recently bought and sold shares of ANVS. Lokken Investment Group LLC grew its stake in Annovis Bio by 60.3% during the first quarter. Lokken Investment Group LLC now owns 29,235 shares of the company's stock worth $44,000 after buying an additional 11,000 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Annovis Bio during the fourth quarter worth about $55,000. Warberg Asset Management LLC acquired a new stake in Annovis Bio during the first quarter worth about $58,000. XTX Topco Ltd acquired a new stake in Annovis Bio during the fourth quarter worth about $59,000. Finally, Atria Wealth Solutions Inc. bought a new position in shares of Annovis Bio in the fourth quarter worth about $65,000. 15.83% of the stock is currently owned by institutional investors and hedge funds.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.